Form 4: BioMarin Executive Henry J. Fuchs Acquires Shares Through RSU Vesting

Henry J. Fuchs, President of Worldwide R&D at BioMarin Pharmaceutical Inc., acquired shares of common stock through the vesting of Restricted Stock Units (RSUs) based on performance metrics.

Summary

• Henry J. Fuchs, President of Worldwide R&D at BioMarin Pharmaceutical Inc., acquired shares of common stock through the vesting of Restricted Stock Units (RSUs) on February 27, 2024.
• The RSUs were earned based on performance metrics related to total shareholder return, strategic goals, and non-GAAP income over the periods spanning 2021 through 2023.
• A total of 30,640 RSUs were earned based on relative total shareholder return, 13,326 RSUs were earned based on strategic goals achieved, and 9,238 RSUs were earned based on non-GAAP income.
• Although earned, the RSUs vest on March 15, 2024, subject to continued service through that date.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions related to equity compensation. The vesting of RSUs suggests that performance targets were met, which is mildly positive, but it's not a major event.

Positives

• The vesting of RSUs indicates that performance targets related to shareholder return, strategic goals, and non-GAAP income were met during the 2021-2023 period.
• The acquisition of shares by a key executive could be interpreted as a positive sign of confidence in the company's future performance.

Future Outlook

The RSUs will vest on March 15, 2024, subject to the reporting person's continued service through that date.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the compensation structure and equity ownership of key executives.

Comparison to Industry Standards

• Equity compensation, including RSUs, is a standard practice in the biotechnology industry to align executive incentives with shareholder value.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar equity-based compensation plans for their executives.
• The specific performance metrics used (total shareholder return, strategic goals, and non-GAAP income) are common benchmarks for evaluating executive performance in the biotech sector.

Stakeholder Impact

• The vesting of RSUs impacts shareholders by increasing the number of outstanding shares.
• The vesting of RSUs incentivizes the executive to continue to perform well, which benefits shareholders.

Next Steps

• The RSUs will vest on March 15, 2024, subject to continued service.

Key Dates